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Abstract: Cervical cancer is one of the most common cancers in women living in developing countries.
Due to a lack of affordable effective therapy, research into alternative anticancer compounds with
low toxicity such as dietary polyphenols has continued. Our aim is to determine whether two
structurally similar plant polyphenols, resveratrol and pterostilbene, exhibit anticancer and anti-HPV
(Human papillomavirus) activity against cervical cancer cells. To determine anticancer activity,
extensive in vitro analyses were performed. Anti-HPV activity, through measuring E6 protein
levels, subsequent downstream p53 effects, and caspase-3 activation, were studied to understand
a possible mechanism of action. Both polyphenols are effective agents in targeting cervical cancer cells,
having low IC50 values in the µM range. They decrease clonogenic survival, reduce cell migration,
arrest cells at the S-phase, and reduce the number of mitotic cells. These findings were significant,
with pterostilbene often being more effective than resveratrol. Resveratrol and to a greater extent
pterostilbene downregulates the HPV oncoprotein E6, induces caspase-3 activation, and upregulates
p53 protein levels. Results point to a mechanism that may involve the downregulation of the HPV
E6 oncoprotein, activation of apoptotic pathways, and re-establishment of functional p53 protein,
with pterostilbene showing greater efficacy than resveratrol.
Keywords: cervical cancer; resveratrol; pterostilbene; HPV E6; p53; cell cycle
1. Introduction
Cervical cancer is one of the most prevalent cancers affecting women worldwide. It is the
second most common cancer in developing countries and 11th in developed countries—these regional
differences are often attributed to the lack of Pap smears, a preventative procedure often absent in
underdeveloped areas [1,2]. It is widely accepted that the etiological factor that causes cervical cancer
is chronic infection of the human papilloma virus (HPV), which is considered the most common
sexually transmitted infection [3]. Every year about 500,000 women acquire the disease and 75% are
from the developing countries [4]. Moreover, recent evidence indicates that HPV infection is on the rise
in men, leading to higher incidences of penile and oropharyngeal cancer [5]. HPVs can be clinically
classified as “low-risk” (LR-HPV) or “high-risk” (HR-HPV) depending on the relative tendency of
the HPV lesions to transform into malignancy. HPV 16 and HPV 18 are the two most important
cancer-causing, high-risk HPV [6]. HPV progression to cancer is dependent on prolonged infection
by these high risk HPV viruses. The progression of HPV lesions to a neoplastic stage is dependent
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on several co-factors. Although there are approved HPV vaccines and drugs available, a problem
is the affordability of these drugs in low income areas [7]. Two such vaccines are Cervarix® and
Gardasil® [8], which renders prophylactic actions against cervical lesions associated with the most
common oncogenic HPV types, 16/18, but effective therapeutic measures for post-infection lesions are
currently not available. The major concern for the common chemotherapeutic medicines like cisplatin
and paclitaxel are their adverse side effects [9,10]. The development of natural chemoprotective drugs
that effectively target HPV infection could drastically reduce the incidence and progression of cervical
cancer worldwide if they are not cost inhibitive and have low side effects.
Of the varied groups of naturally occurring antioxidants, polyphenols have gained increased
importance in cervical cancer since they have displayed potent antitumor properties in a number of
cancers by targeting several pathways that are involved in cancer progression [11,12]. The current
article uses cervical cancer cells to compare the tumor-inhibitory effects and mechanism of action of
two such polyphenols, resveratrol and pterostilbene. Both resveratrol and pterostilbene are stilbenes,
which is a class of natural polyphenolic compounds that have been studied for their anticarcinogenic
activities. Resveratrol (3,4,5-trihydroxy-trans-stilbene) has been isolated from grapes, red wine, purple
grape juice, peanuts, berries, and some medicinal plants [13]. Resveratrol is a widely studied stilbene
compound having very low toxicity in the human system, and it is also known to modulate several
pathways that are directly linked to cancer progression [14]. Both in vitro and in vivo cancer studies
have shown resveratrol to inhibit cell proliferation and angiogenesis along with inducing pro-apoptotic
properties [15]. The potential problem of using resveratrol as a chemoprotective agent is that it has
low systemic bioavailability, which might lower its efficacy in the human system [16]. In order
to overcome this, several efforts are being made to develop resveratrol derivatives with higher
systemic bioavailability [17]. Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a naturally
derived dimethylether analogue of resveratrol. Pterostilbene is believed to be produced in plants as
a defense mechanism against some external microbial or fungal infection and is therefore considered
a phytoalexin [18]. It has been isolated from grapevine leaves and blueberries [19]. Recently,
pterostilbene has gained much attention as a possible anticancer agent, showing no toxicity in humans
up to a dose of 250 mg/day [20].
Although the chemical structure of pterostilbene is closely related to resveratrol, the substitution
of the hydroxyl group with a methoxy group in pterostilbene is believed to make the molecule more
stable as well as increase its capacity to enter cells [21]. In addition, clinical studies have shown that the
half-life and oral bioavailability of pterostilbene are significantly greater than those of resveratrol [20].
Studies on colon cancer cell lines have shown pterostilbene to be more potent than resveratrol in
inhibiting DNA synthesis and in decreasing the expression of inflammatory genes responsible for
cancer progression [22]. Although studies in other types of carcinomas show the potential efficacy
of resveratrol and pterostilbene, there has been no study to the best of our knowledge that explores
an anticancer mechanism that is specific for HPV-positive carcinoma. An in silico docking study
has shown that resveratrol interacts with the p53 binding site of E6 residues [23]. E6 is a vital HPV
oncoprotein essential for cervical cancer progression. E6 binds to tumor suppressor protein p53 and
targets it for degradation by the ubiquitin proteasome pathway [24], thus causing uncontrolled cell
proliferation. Here, we set out to compare the relative effectiveness of resveratrol against pterostilbene
on cervical cancer cells, paying particular attention to their comparative IC50 values, changes in the
levels of the HPV oncoprotein E6 and its target p53, as well as their comparative pro-apoptotic and
anti-migratory capacities.
2. Materials and Methods
2.1. Cell Culture
Human cervical carcinoma HeLa cells were obtained from a commercial supplier (American
Type Culture Collection, Manassas, VA, USA) and were cultured in Dulbecco’s Modified Eagle
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Medium: Nutrient Mixture F-12 (DMEM/F-12) (HyClone, GE Healthcare Life Sciences, Manassas,
VA, USA), supplemented with 10% fetal calf serum (HyClone, GE Healthcare Life Sciences) and 0.1%
Penicillin-Streptomycin Solution (HyClone). Cells were incubated in a 37 ◦C incubator with 5% CO2.
2.2. Determination of IC50 Using WST-1 Assay
Seven thousand cells were plated on 96-well plates and allowed to grow for 24 h. Resveratrol
(Acros, #430075000) or pterostilbene (TCI, #P1924) was serially diluted from 10–120 µM into
DMEM/F-12 plus 1× insulin-transferrin-selenium (ITS) supplement (Invitrogen). Cells were treated
with dilutions (in triplicate) for 24 h prior to performing a WST-1 (Water Soluble Tetrazolium salt-1)
cell viability assay. The WST assay involved aspiration of the medium after treatment and rinsing
three times with equal volumes of 1×Phosphate Buffered Saline (PBS), followed by the addition of
80 µL of 10% WST-1 (Clontech, Mountain View, CA, USA) in DMEM to each well. The plate was
then incubated at 37 ◦C for 1 h and absorbance monitored at 440 nm using a plate reader. Results
obtained were analyzed using GraphPad Prism 5 software to determine the IC50 using a standardized
method [25,26].
2.3. Live Imaging
Images of untreated and treated (with resveratrol and pterostilbene) cells were taken every 10 min
for 24 h to generate video files using a Zeiss Axio Observer Z1 microscope.
2.4. Clonogenic Assay
Two hundred thousand cells were plated on 6-well plates and allowed to grow for 24 h prior to
treatment with pterostilbene (50 µM) and resveratrol (50 µM) for 24 h. After 24 h, cells were trypsinized
to single cell suspensions. After cell counting, 150 viable cells from each treatment set were plated in
one well from a 6-well plate and allowed to grow in complete DMEM/F-12 medium for 15 days. After
said period of time, cells were washed once with 1× PBS then fixed and stained with 0.5% crystal
violet in 6% glutaraldehyde for 30 min. The cells were briefly rinsed with tap water and allowed to air
dry. Images of each well was taken and colonies were counted using ImageJ (NIH, Bethesda, Rockville,
MD, USA). The plating efficiency and survival factor was calculated as determined previously [27].
2.5. Scratch Assay
Twelve thousand cells were grown on 96-well plates until a confluent monolayer was formed.
A scratch was made with a sterile p200 tip in each well through the center of the culture. The debris
was washed off with serum-free media and a marking was made on the bottom of the plate to take
images at the same location. Cells were then treated with different concentrations (5 µM and 20 µM) of
resveratrol or pterostilbene and brightfield images were taken after 48 h to allow closure of the control
scratch. The images were analyzed using ImageJ and the area of closure was measured according to
previous published methods [28].
2.6. Flow Cytometry
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol or pterostilbene (5 µM, 10 µM, and 15 µM) for 18 h. Cells were trypsinized, centrifuged,
and washed with 0.1% Fetal Calf Serum (FCS) in 1× PBS solution and resuspended in 70% ethanol at
−20 ◦C, which was added dropwise while shaking the samples vigorously. Fixed samples were kept
at 4 ◦C for 1 h followed by washing twice in 1× PBS. Prior to flow cytometry, cells were incubated
with RNase (500 µg/mL) for 30 min at 37 ◦C and then stained with propidium iodide (PI; 70 µM) for
30 mins. Cells were analyzed for DNA content by measuring PI fluorescence using an Accuri C6 flow
cytometer (BD).
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2.7. Western Blot Analysis
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol (10 µM, 50 µM) or pterostilbene (10 µM, 50 µM) for a period of 22 h. Extraction
of proteins from cultured cells was performed using M-PER Mammalian protein extraction reagent
(Thermo Fisher, Waltham, MA, USA) with protease and phosphatase inhibitors. The total amount
of protein in each well was quantified using the Lowry method. To resolve the proteins, 25 µg of
protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 10%
acrylamide separating gel and then transferred to nitrocellulose membrane for 1 h. The membrane was
blocked at room temperature for 1 h with 5% nonfat dry milk in Tris Tween Buffered Saline (TTBS).
The nitrocellulose membrane was then incubated overnight with a p53 antibody (sc-6243) followed by
incubation at room temperature for 1 h with anti-rabbit IgG conjugated with horseradish peroxidase.
SuperSignal West Pico chemiluminescence substrate (Pierce) was used for detection following the
manufacturer’s instructions. The membranes were scanned using APHA INNOTECH Fluorchem SP
imaging system. Analysis of blots was done using ImageJ software.
2.8. Immunocytochemistry
Seven thousand HeLa cells were plated on 8-well chamber slides and allowed to grow for 48 h.
Cells were then treated with different concentrations of resveratrol (5–50 µM) or pterostilbene (5–50 µM)
for 22 h (for study of E6, p53 and cleaved caspase-3) and 18 h (for study of Phospho histone H3).
All drug treatments were performed in serum-free DMEM/F-12 containing 1% supplement (ITS;
insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After treatment, cells were fixed
in 4% paraformaldehyde at room temperature, rinsed with 1× PBS, and then permeabilized and
blocked with 10% horse serum, 2% bovine serum albumin, and 0.5% Triton X-100 in PBS for 1 h.
The cells were then incubated overnight with primary antibodies in blocking buffer. Subsequent
to primary antibody treatment, the cells were washed and then incubated with the respective
Fluorescein isothiocyanate (FITC) conjugated secondary antibodies for 3 h, followed by incubation
with 4’,6-diamidino-2-phenylindole (DAPI) (10 µg/mL) and three washes with 1× PBS. The slides
were then mounted with coverslips and cell images were acquired using a Zeiss Axio Observer Z1
microscope and an AxioVision 4.6.3-AP1. Images of different, randomly chosen fields were acquired
with identical exposure times from each well for quantification. ImageJ was used to measure the
fluorescence intensity and cell counting. The fluorescence intensities of E6 and P53 antibodies were
normalized to DAPI intensity (blue).
Antibodies Used: E6 antibody (sc-460, Santa Cruz Biotechnology, Dallas, TX, USA), p53 antibody
(sc-6243), cleaved caspase-3 antibody (D175, 9661, CST), Phospho Histone H3 (Ser 10) antibody (06–570,
Millipore, Burlington, MA, USA).
2.9. Statistical Analysis
Statistical analyses were performed using Microsoft Excel® 2013 (Microsoft Corporation,
Redmond, WA, USA) and GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla, CA, USA). Means
and standard deviations were calculated for each group. One-way ANOVA with Tukey test was
used to compare three or more datasets and determine the significance between the groups. ANOVA
is a test of variance and post hoc Tukey test used is for the determination of significance between
groups [29,30]. p < 0.05 was considered as significant.
3. Results
3.1. Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to Resveratrol
In order to study the comparative cytotoxicity of pterostilbene and resveratrol on HeLa tumor
cells, brightfield images (Figure 1A) and WST-1 cell viability assays (Figure 1B) were performed
24 h post-treatment. The brightfield images taken after 24 h of treatment (Figure 1A) showed that
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pterostilbene (40 µM) eliminates significantly more cells than resveratrol at the same concentration.
Live imaging of cells treated with 60 µM of the two compounds show significantly more death
and characteristic apoptotic blebbing in pterostilbene-treated cells when compared to untreated or
resveratrol-treated cells (Supplementary Videos S1–S3). The WST-1 analysis revealed that although
both pterostilbene and resveratrol eliminated HeLa cells significantly and in a dose-dependent manner,
pterostilbene displayed a 1.97-fold lower IC50 when compared to resveratrol (42.3 µM vs. 83.5 µM;
p < 0.05; Figure 1B). Additionally, both compounds, at 50 µM, significantly inhibited the clonogenicity
of post-treated cells in a 15-day clonogenic assay (Figure 1C). Pterostilbene significantly reduced
clonogenic survival by 87.5% compared to the control (p < 0.05), while resveratrol inhibited it by 63%
(p < 0.05) (Figure 1C). Moreover, the difference between the survival percentages of the two treatment
groups is significant (p < 0.05).
Figure 1. Pterostilbene is more potent in eliminating HeLa cervical cancer cells as compared to
resveratrol: (A) Brightfield analysis of HeLa cells untreated (Ai) or treated for 24 h with 40 µM of
resveratrol (Res; Aii) or 40 µM of pterostilbene (Pte; Aiii). Evidence of cell elimination was only seen
robustly in cells treated with pterostilbene at 40 µM. (B) Analysis of IC50 values, generated by a Water
Soluble Tetrazolium salt-1 (WST-1) assay after 24 h of exposure to resveratrol or pterostilbene indicates
that pterostilbene (IC50 = 42.3 µM) is a more potent cytotoxic agent than resveratrol (IC50 = 83.5 µM;
Bii). The graphs represent data from three independent experiments (mean ± S.E.M. (Standard error
mean)). (C) Clonogenic assays performed to compare the relative effect of the two polyphenols on
the clonogenicity of HeLa cells untreated (Ci) or treated with 50 µM of either resveratrol (Cii) or
pterostilbene (Ciii). Results are from 15-days post-treatment and indicate that pterostilbene is more
efficient in curbing the clonogenicity compared to resveratrol (Civ). Bar graph represents data from
three independent experiments (mean ± S.E.M.; * p < 0.05; Civ).
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3.2. Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and Resveratrol
To determine the comparative efficacy of resveratrol and pterostilbene in inhibiting HeLa cell
migration, two different sub-lethal concentrations of each compound were used in a 48-h scratch
assay (Figure 2). Based on the WST-1 results and brightfield images (unpublished), we found that
cells treated with a concentration below 25 µM showed no signs of cellular toxicity. To avoid any
cytotoxicity, we used lower concentrations of 5 µM and 20 µM. At sub-lethal concentrations of 5 µM
and 20 µM, both resveratrol and pterostilbene significantly inhibited HeLa cell migration relative to
untreated cells (p < 0.05; Figure 2). Pterostilbene was more effective in inhibiting HeLa cell migration at
20 µM when compared to resveratrol; however, this result was not significant and no differences were
seen between the two compounds at 5 µM (Figure 2). In an effort to analyze the effects of resveratrol
and pterostilbene on cell migration, we normalized the amount of migration into the scratch (wound)
by untreated cells, to 100%. Relative to this control, resveratrol-treated cells migrated only 71.2%
(5 µM) and 63.7% (20 µM), while cells treated with pterostilbene migrated only 69.5% (5 µM) and 49.2%
(20 µM) (Figure 2).
Figure 2. Resveratrol and pterostilbene inhibit cell migration: (A) HeLa cells were monitored for cell
migration into a scratched “wound”. Cells were either untreated or treated with sub-lethal concentrations
(5 µM and 20 µM) of resveratrol (Res) or pterostilbene (Pte). The extent of migration into the scratched
area was calculated after 48 h and revealed that both resveratrol and pterostilbene significantly inhibit cell
migration, although pterostilbene had greater anti-migratory effect. (B) The graphs represents data from
triplicate sample experiments normalized to the control (mean % migrated cells ± S.E.M.; * p < 0.05).
Scale bar: 0.05 µm.
3.3. Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of Resveratrol
and Pterostilbene
In order to compare the effect of sub-lethal doses of either resveratrol or pterostilbene on the
cell cycle of HeLa cells, treatment was carried out with three different concentrations (5 µM, 10 µM,
and 15 µM) of the two compounds for 18 h prior to flow cytometric analysis (Figure 3A). Flow
cytometry analysis showed that the cells treated with either compound exhibited a significant
decrease in the number of cells in the G2-M phase with respect to the control cells (p < 0.05)
(Figure 3A,B, Table 1), indicating an S-phase cell cycle arrest. This effect corresponded with an
increase in the number of cells arrested at the S-phase. Pterostilbene was significantly more potent
than resveratrol in inhibiting cell cycle progression, showing effects at concentrations as low as
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5 µM (p < 0.05) (Figure 3A,B, Table 1). At this concentration, pterostilbene had these percentages
of cells in each phase: G1 = 53.4 ± 1.4, S = 34 ± 1.4, G2 =12.5 ± 0.2, while resveratrol had values of
G1 = 64.8 ± 2.0, S = 16.3 ± 1.0, G2 = 18.3 ± 2.3. At a higher concentration (15 µM) both compounds
significantly inhibited cells from entering into G2-M by arresting them in the S-phase, and difference
between the extent of the arrest at this phase induced by the two compounds was significant (p < 0.05)
(Figure 3A,B, Table 1).
To confirm the cell cycle data, which indicated that both compounds are potent inhibitors of cells
entering into G2-M, we investigated the status of the M-phase mitotic marker phospho-histone-H3
by immunocytochemistry (Figure 3C,D). At concentrations of 10 µM, both compounds significantly
suppressed the amount of cells positive for the mitotic marker phospho-histone-H3, when compared
to the untreated cells control. Although resveratrol significantly suppressed the abundance of
phospho-histone-H3 (mitotic cells) at 5 µM, when compared to the control cells, pterostilbene at
this concentration was significantly more potent than resveratrol (Figure 3D). Relative to the control,
which was set at 100%, cells treated with 5 µM pterostilbene exhibited only 13.8% mitotic cells positive
for the marker, which was significantly lower than the resveratrol-treated sample at this concentration,
which had 60% mitotic cells (Figure 3D; p < 0.05).
Figure 3. S-phase arrest in HeLa cells treated with low concentrations of resveratrol and pterostilbene:
(A) Flow-cytometric evaluation of HeLa cells untreated or treated with sub-lethal doses of resveratrol
(Res) and pterostilbene (Pte) for 18 h. Treated cells exhibited S-phase arrest and a subsequent decrease
in the number of cells in G2/M. Pterostilbene was a more potent compound than resveratrol, showing
a capacity to arrest cells at the S-phase at concentrations as low as 5 µM. (B) Graphical representation
of the dose-dependent cell cycle effects induced by resveratrol and pterostilbene at three different
concentrations (5 µM, 10 µM, and 15 µM). (B) The graph represents data from triplicate sample
experiments normalized to the control (mean % cells in each phase ± S.E.M.) (C) Immunofluorescent
images of HeLa cells probed for the M-phase marker phospho-histone-H3 (serine10). HeLa cells
were untreated or treated with 5 µM and 10 µM of resveratrol or pterostilbene. Immunofluorescent
images display a decrease of histone-H3 in cells treated with both the compounds, the effects at 5 µM
of pterostilbene is much greater than those of resveratrol (at 5 µM). (D) Graphical representation of
the percent of mitotic cells calculated from immunofluorescent images reveal that resveratrol and to
a greater extent pterostilbene are effective in decreasing the number of mitotic HeLa cells. The graph
represents data from experiments obtained from triplicate samples normalized to the control (mean %
mitotic cells ± S.E.M.;* p < 0.05).
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Table 1. Table showing the percentage of cells in each phase of the cell cycle (% ± S.E.M.) after treatment
with different concentrations of resveratrol (Res) and pterostilbene (Pte).
G1 ± S.E.M. S ± S.E.M. G2 ± S.E.M.
Control 64.1 ± 0.4 8.00 ± 2.5 27.7 ± 2.4
Res 5 µM 64.8 ± 2.0 16.3 ± 1.0 18.3 ± 2.3 ˆ
Pte 5 µM 53.4 ± 1.4 + 34.0 ± 1.4 * 12.5 ± 0.2 ˆ
Res 10 µM 58.5 ± 0.2 26.5 ± 0.2 * 14.4 ± 1.0 ˆ
Pte 10 µM 54.3 ± 0.8 + 35.6 ± 2.4 * 10.1 ± 1.5 ˆ
Res 15 µM 61.3 ± 1.9 27.1 ± 0.8 *,# 11.5 ± 1.2 ˆ
Pte 15 µM 52.3 ± 2.0 + 40.1 ± 3.4 *,# 7.7 ± 0.5 ˆ
+ p < 0.05 relative to G1 control, * p < 0.05 relative to S control, ˆ p < 0.05 relative to G2 control, # p < 0.05 relative to
each other.
3.4. Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in HeLa Cells Treated
with Pterostilbene and Resveratrol
In order to investigate how resveratrol and pterostilbene were affecting HeLa cell survival and
cell cycle progression, we treated cells with either of the two compounds at sub-lethal (10 µM)
and higher (50 µM) concentrations prior to analysis by immunostaining for E6, active caspase-3,
and p53 (Figure 4A–C). At 10 µM, both resveratrol and pterostilbene failed to significantly affect
levels of E6 and active caspase-3 levels relative to the control (Figure 4A,B). However, at 50 µM
both compounds significantly suppressed E6 levels and elevated cleaved caspase-3 levels in treated
cells relative to the untreated cells (Figure 3A–C). At this concentration (50 µM), pterostilbene was
significantly more potent than resveratrol at suppressing E6 levels (resveratrol = 0.77 ± 0.11: 23%
decrease vs. pterostilbene = 0.57 ± 0.06: 43% decrease; p < 0.05) and simultaneously elevating active
caspase-3. It should be noted that we were unable to detect any noticeable differences in the sub-cellular
localization of E6 in treated cells (Figure 4A).
Nutrients 2018, 10, 243 9 of 15
Figure 4. Downregulation of viral oncoprotein E6 and upregulation of active-caspase-3 in HeLa cells
treated with resveratrol or pterostilbene: (A) HeLa cells immunostained for E6 levels (green) and
counterstained with the nuclear dye 4’,6-diamidino-2-phenylindole (DAPI) (blue) after treatment with
resveratrol (Res) and pterostilbene (Pte; 10 µM and 50 µM). Loss of E6 proteins are visually evident
in cells treated with 50 µM of either resveratrol or pterostilbene. (B) Cell image analysis of the E6
fluorescent data revealed a significant 43% decrease of E6 protein levels in HeLa cells treated with
pterostilbene at 50 µM and a 23% decrease of E6 levels in cells treated with resveratrol, both relative to
the control. The graph represents data from experiments obtained from three independent experiments
normalized to the control (mean % normalized to DAPI ± S.E.M.; * p < 0.05). (C) Immunofluorescent
images probing for active-caspase-3 (green) shows a corresponding enhanced activation of this mediator
of apoptosis by both resveratrol and pterostilbene.
3.5. Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with Pterostilbene and Resveratrol
Concomitant with E6 suppression, 50 µM pterostilbene treatment for 22 h caused an upregulation
of p53 in HeLa cells (Figure 5A,B). When compared to the control, pterostilbene treatment elicited
a 2-fold increase in p53 levels (staining normalized to DAPI; Figure 5B; p < 0.05). In comparison to
the control, HeLa cells treated with 50 µM of resveratrol also caused an upregulation of p53 (1.75-fold
increase; Figure 5A,B; p < 0.05) at 22 h.
Total protein levels of p53 were also analyzed by Western blot in cells treated with either resveratrol
(10 µM and 50 µM) or pterostilbene (10 µM and 50 µM) for 22 h (Figure 5C,D). Both compounds
elevated p53 levels at 50 µM; however, significance was only noted in cells treated with pterostilbene
at this concentration (Figure 5C,D). Although cells treated with pterostilbene at 10 µM tended to have
elevated p53 protein levels relative to both the control cells and cells treated with 10 µM of resveratrol,
these differences were not significant based on an ANOVA test (Figure 5C,D).
Nutrients 2018, 10, 243 10 of 15
Figure 5. Upregulation of the tumor suppressor protein p53 in HeLa cells treated with resveratrol
and pterostilbene: (A) Immunoflourescent images of p53 protein (green) untreated or after treatment
with 50 µM of either resveratrol (Res) or pterostilbene (Pte) for 22 h. Levels of p53 are elevated
in cells treated with either polyphenol. (B) Image analysis of p53 immunofluorescence indicates
that pterostilbene treatment at 50 µM elicited a significant 2-fold increase in p53, while resveratrol
exposure at similar concentrations induced a significant 1.75 increase in p53. The graph represents data
from experiments obtained from three independent experiments normalized to the control (mean %
normalized to DAPI ± S.E.M. * p < 0.05). (C) Western blot analysis also revealed that the elevation of
p53 protein levels is evident in HeLa cells treated with 50 µM of resveratrol and pterostilbene; however,
significant differences relative to the control were only reached with HeLa cells treated pterostilbene at
50 µM. (D) The graph represents data from experiments obtained from three independent experiments
normalized to the control (mean % normalized to beta-actin ± S.E.M.; * p < 0.05).
4. Discussion and Conclusions
In the current study, for the first time to our knowledge, we have compared the antitumor
potency of resveratrol and pterostilbene on E6+ cervical cancer cells in vitro. We demonstrated that
pterostilbene was significantly more potent than resveratrol in eliminating and in abrogating the
clonogenicity of these cervical cancer cells (Figure 1). To assess and study the effects of the two
compounds, we used a wide range of concentrations. Sub IC50 concentrations ranging from 5–20 µM
were used to understand the action of these polyphenols at a low concentration. The results show that
at these concentrations the polyphenols can inhibit cell division and migration. To further understand
the cytotoxic mechanisms, it was imperative for us to look at supra IC50 concentrations. We used
50 µM to understand the mechanism of action. The clonogenic assay using this high concentration
elucidates the long-term effect of these polyphenols on surviving cells even after the removal of
treatment. While sub-IC50 values of both compounds inhibited the migration of E6+ cervical cancer
cells, a higher sub-lethal concentration of resveratrol (20 µM) was needed to exert any significant
inhibitory effect. Nonetheless, pterostilbene caused a more significant degree of inhibition to cell
migration, attesting its superior antitumor potency (Figure 2). It is a notion held by cancer researchers
that sub-IC50 concentrations of chemotherapeutic drugs are ineffective in curtailing tumor malignancy.
However, surprisingly, our data shows that even at a low sub-lethal concentration (5 µM), pterostilbene
is more effective than resveratrol as an antiproliferative agent against cervical cancer cells by triggering
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cell cycle arrest at the S-phase (Figure 3). In addition to being effective at sub-IC50 concentrations,
the supra-IC50 concentration of pterostilbene (50 µM) was also superior to resveratrol (at 50 µM) in
suppressing E6 while upregulating p53 and active-caspase-3 expression, thus causing a greater degree
of apoptosis-mediated cell elimination. This observed suppression of E6 and upregulation of p53 is of
paramount importance because HPV infection and cancer progression in cervical cells relies on the
expression of the viral E6 oncoprotein which targets p53 for degradation by the ubiquitination [24,31].
Thus, untreated cervical cancer cells continue to proliferate in the absence of p53, unable to respond
to cell stress and DNA damage. Our data indicates that resveratrol and pterostilbene may restore an
adequate p53 response and ultimately act as anticancer plant compounds.
A comparative study between resveratrol and pterostilbene on colon cancer cells had shown
pterostilbene to be a more potent anticancer agent compared to resveratrol [15]. Our first approach to
understand the comparative efficacy of resveratrol and pterostilbene in HeLa cells was a cytotoxicity
analysis, in addition to ascertaining the inhibitory concentration (IC50) (Figure 1 and Videos S1–S3).
The results clearly indicated that pterostilbene could eliminate HeLa cells much faster and at
a significantly lower concentration compared to resveratrol. We also further analyzed the cytotoxic
potential of these polyphenols on a second cell line, E6-positive murine TC1 cells, and found a similar
trend in IC50 results for resveratrol and pterostilbene, where pterostilbene is 2-fold more cytotoxic than
resveratrol [32]. Since cancer cells are known to have enhanced clonogenecity [27,33], our study aimed
to see the survival capability of the cells treated with supra-IC50 concentrations of either resveratrol or
pterostilbene. Clonogenic studies show the long term-term effects of these polyphenols on cervical
cancer cells after treatment for 24 h and then allowing the surviving cells to grow in normal growth
medium for 15 days. Both compounds at supra-IC50 concentrations showed a dramatic decrease in the
clonogenic capacity of the surviving cells. These results suggest that resveratrol and pterostilbene may
suppress new tumor growth often seen in high-grade metastatic cervical cancer.
The migration of cancer cells is a very important factor responsible for the metastasizing of
cancers [34]. Inhibition of migration can play a major role in checking the progression of cancer
metastasis. Our study found that sub-cytotoxic doses of both compounds exhibit anti-migratory
roles. These findings are supported by previous studies, which have shown that resveratrol shows
anti-migratory activity by suppressing phorbol 12-myristate 13-acetate (PMA)-induced migration in
cervical cancer cells [35]. Studies in hepatocellular carcinoma indicate that pterostilbene suppresses
migration by downregulating MMP-9 expression [36]. These mechanisms might possibly be
responsible for inhibiting migration in HeLa cells and remain to be determined in later studies.
Previous cell cycle arrest studies of resveratrol on HeLa cells showed that all the cells were
arrested at the S-phase and none remained in the G2/M-phase [37,38]. Pterostilbene shows cell cycle
arrest in several cancer studies [39]; however, to the best of our knowledge, no such study on cervical
cancer has been carried out. Our current study showed that pterostilbene shows markedly better
efficacy than resveratrol in arresting the cell cycle at the S-phase. To further analyze the effects of the
two compounds on cell cycle arrest, we looked at phospho-histone H3 as a marker for mitosis [40].
Our observations strengthen and confirm the results obtained from flow cytometric analysis indicating
that although both compounds are able to arrest mitosis, pterostilbene has enhanced capacity to arrest
cancer cell growth.
Although we initially used sub-lethal concentrations of the two compounds on HeLa cells to
decipher their antitumor mechanisms in the context of cell cycle arrest, it was imperative for us
to delineate the possible mechanism of elimination of HeLa cells by these compounds at higher
concentrations. Pterostilbene is known to be effective on cervical cancer cells by Endoplasmic reticulum
(ER)-mediated stress development as well as by targeting the Nrf-2 pathway [41]. In HPV+ cancer
cells, the oncoprotein E6 degrades the tumor-suppressor protein p53 by targeting it for proteasomal
ubiquitination, which has been shown to augment the tumorigenic characteristics of cancer cells [24,42].
In contrast, inhibition of E6 expression in the cancer cells would be expected to allow p53 protein to
trigger apoptosis and cell cycle arrest. Our findings support this latter statement, with resveratrol
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and pterostilbene activating caspase-3 while simultaneously downregulating E6 and upregulating
p53. Our findings are partly supported by previous studies indicating that resveratrol treatment on
cervical cancer cell lines upregulates p53 [43]. Our findings are the first to show a direct upregulation
of p53 in HeLa cells by another polyphenol, namely, pterostilbene. Importantly previous studies have
shown that p53 and simultaneous caspase-3 activation might be the key for triggering apoptosis in
HeLa cells [44]. Our experiments support this finding and ascertain that resveratrol and pterostilbene
act as robust agents capable of regulating the p53-dependent apoptotic pathway. The p53 protein,
which is usually very low in HeLa cells, was upregulated by resveratrol and pterostilbene, leading
us to hypothesize that reactivation of p53 in treated HeLa cells is a possible mechanism of action of
these compounds.
Cervical cancer is a major concern in developing countries due to lack of affordable prophylaxis
and treatment. As present modes of treatment like surgery, chemotherapy, or radiation involve
high systemic toxicity, there is an urgent need to find affordable alternative therapies. Diet-based
polyphenols like resveratrol and pterostilbene are therefore potential candidates for the effective
therapy of cervical cancer with significantly low toxicity. We found pterostilbene to be a more potent
anticancer agent than resveratrol in HeLa cells. This difference may be a function of pterostilbene
being capable of upregulating p53 and downregulating E6 significantly more than resveratrol.
As pterostilbene is non-toxic to normal cells [20], it has the potential to be a robust, cost-effective
anti-E6+ tumor drug. Others have found that that pterostilbene possess greater bioavailability and
stability [45] than resveratrol in vivo (80% vs. 20%). Resveratrol has been shown to be non-toxic to
several cells lines like glial cells and neurons, even after a treatment dose of 100 µM for 48 h [46]. Other
studies on normal fibroblasts also state the non-toxicity of resveratrol at our observed potent anticancer
concentrations [47]. Additionally, pterostilbene shows no toxicity at these concentrations in normal
skin fibroblasts and myoblasts [48]. According to clinical studies, the safe dosage for resveratrol and
pterostilbene is 5 g/day [49] and 250 mg/day [20], respectively. Our initial in vivo studies in the
laboratory using a non-toxic dosage of both resveratrol and pterostilbene has shown promising results
in inhibiting tumor growth in a model of cervical cancer [32]. Taken together, our findings support the
further evaluation of pterostilbene as a possible therapy against cervical cancer.
Here, we show that pterostilbene potently suppresses HPV E6 expression (Figure 4) and efficiently
eliminates HPV+ cells in culture by p53-mediated apoptosis (Figures 1 and 5) while suppressing
cell proliferation (Figure 3) and migration (Figure 2). We find that pterostilbene is a more promising
agent against cervical cancer when compared to resveratrol. Based on such properties, the use of
pterostilbene presents a relatively economical but highly hopeful therapeutic approach to treat HPV
infections and cervical cancers. Our future studies will include signaling studies using HPV+ murine
tumor models to confirm these observations in vivo.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/10/02/243/s1,
Video S1: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse video of cells untreated;
Video S2: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse video of cells treated
with 60 µM resveratrol; Video S3: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse
video of cells treated with 60 µM pterostilbene obtained for 24 h showing elevated blebbing and cell death in
pterostilbene treatment.
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